The updated results of zevorcabtagene autoleucel (zevor-cel; R&D code: CT053, an autologous CAR T-cell product targeting BCMA) and CT071 (an autologous CAR T-cell product targeting GPRC5D) have been presented at the 29th Annual Congress of the European Hematology Association (“EHA”). https://lnkd.in/gEKkNrwb #cartcelltherapy #eha2024 #multiplemyeloma #bcma #gprc5d #carcelerate
关于我们
科济药业(股票代码:2171.HK)是一家在中国及美国拥有业务的生物制药公司,主要专注于治疗血液恶性肿瘤和实体瘤的创新CAR-T细胞疗法。我们建立了一个综合细胞治疗平台,其内部能力涵盖从靶点发现、抗体开发、临床试验到商业规模生产。我们通过自主研发新技术以及拥有全球权益的产品管线,以解决CAR-T细胞疗法的重大挑战,比如提高安全性,提高治疗实体瘤的疗效和降低治疗成本。我们的使命是成为能为全球癌症患者带来创新和差异化的细胞疗法,并使癌症可治愈的全球生物制药领导者。
- 网站
-
http://www.carsgen.com
科济药业的外部链接
- 所属行业
- 生物技术
- 规模
- 501-1,000 人
- 总部
- Shanghai,Shanghai
- 类型
- 上市公司
- 创立
- 2014
- 领域
- oncology、hematologic malignancies、solid tumors和CAR T-cell therapies
地点
科济药业员工
动态
-
The preliminary results of Phase I of CT071 (NCT05838131) were presented as a poster at the 29th EHA Annual Congress on June 14, 18:00 - 19:00 CEST, which was titled "First-in-human study of GPRC5D-targeted CAR T cells (CT071) with an accelerated manufacturing process in patients with relapsed/ refractory multiple myeloma (RRMM)" https://lnkd.in/g3R_eYun #eha #eha2024 #rrmm #cartcelltherapy #gprc5d
CARsgen Presents First-in-human Results of GPRC5D Targeting CAR-T CT071 at EHA 2024
en.prnasia.com
-
The final follow-up results of the investigator-initiated trial CT041-CG4006 (NCT03874897) of satricabtagene autoleucel ("satri-cel", CT041) (an autologous CAR T-cell product candidate against Claudin18.2) have been published in Nature Medicine on June 3, 2024. Data were presented as an oral presentation at the 2024 American Society of Clinical Oncology ("ASCO") Annual Meeting. https://lnkd.in/gnsCAqeq
CARsgen Presents Updated Results on Satri-cel in Nature Medicine and at 2024 ASCO
prnewswire.com
-
The abstracts of zevorcabtagene autoleucel (R&D code: CT053, an autologous CAR-T product against BCMA) and CT071, an autologous CAR T-cell therapy candidate targeting G protein-coupled receptor class C group 5 member D (GPRC5D), have been accepted for oral presentation and poster presentation, respectively, at the 29th Annual Congress of the European Hematology Association (“EHA”). https://lnkd.in/gKvJ8XEc #EHA #hematology #cartcells #cartcelltherapy #multiplemyeloma
Newsroom
carsgen.com
-
An abstract of satricabtagene autoleucel (“satri-cel”, CT041) (an autologous CAR T-cell product candidate against Claudin18.2) has been accepted for oral presentation at the American Society of Clinical Oncology (“ASCO”) Annual Meeting 2024. Abstract Title Claudin18.2-Targeted Chimeric Antigen Receptor T Cell-Therapy for Patients with Gastrointestinal Cancers: Final Results of CT041-CG4006 Phase 1 Trial https://lnkd.in/gMjEjdr7 #ASCO2024 #cartcell #cartcelltherapy #oncology #gastriccancer #gastrointestinalcancer
News
carsgen.com
-
"In 2023, CARsgen remained dedicated to our vision, 'Making Cancer Curable' and were committed to reinforcing our team and improving operational efficiency. We made substantial progresses in the regulatory and clinical development of our innovative products and the advancement of new technology platforms. Multiple important milestones for different product candidates across clinical, regulatory, and business development were achieved. We are optimistic that we will navigate and overcome the challenges ahead with resilience and determination, advancing our innovative cell therapies." said Dr. Zonghai Li, Founder, Chairman of the Board, Chief Executive Officer, and Chief Scientific Officer of CARsgen Therapeutics. https://lnkd.in/gbe6KvNC
CARsgen Announced 2023 Annual Results
en.prnasia.com
-
The National Medical Products Administration ("NMPA") of China has approved the New Drug Application ("NDA") for zevorcabtagene autoleucel (R&D code: CT053, an autologous CAR-T product candidate against BCMA), for the treatment of adult patients with relapsed or refractory multiple myeloma who have previously progressed after at least 3 lines of therapy (including a proteasome inhibitor and immunomodulator agent). https://lnkd.in/gag2uvdh. #cartcelltherapy #multiplemyeloma
NMPA Approves the NDA for CARsgen's BCMA CAR-T Therapy Zevorcabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma
prnewswire.com
-
At the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium ("ASCO GI"), CARsgen presented a poster with study results for satricabtagene autoleucel ("satri-cel", R&D code: CT041, an autologous CAR-T product candidate against Claudin18.2), which include the dose escalation results of the Phase 1b ELIMYN18.2 study (Cohort A) in gastric/gastroesophageal (GC/GEJ) or pancreatic cancer (PC) in the US. https://lnkd.in/gCHDQ-af #cartcelltherapy #gastriccancer #pancreaticcancer
CARsgen's Presents Updated Research Results on CT041 at 2024 ASCO GI Meeting
prnewswire.com
-
CT011, an autologous CAR T-cell product candidate against Glypican-3 (GPC3), has achieved Investigational New Drug (IND) clearance from the National Medical Products Administration (NMPA) for patients with GPC3-positive stage IIIa hepatocellular carcinoma who are at high risk of recurrence after surgical resection. https://lnkd.in/g7JeuUcF
CARsgen's CT011 achieves IND clearance from the NMPA for the GPC3-positive stage Ⅲa hepatocellular carcinoma at high risk of recurrence after surgical resection
en.prnasia.com